Head & Shoulders, Xolegel form duo
This article was originally published in The Rose Sheet
Executive Summary
Barrier Therapeutics will package a 1.7-oz. bottle of Procter & Gamble's Head & Shoulders anti-dandruff shampoo alongside its seborrheic dermatitis treatment Xolegel in Xolegel Duo, drug company announces May 22. Kit will offer patients a complete treatment regimen for seborrheic dermatitis, an inflammatory skin condition that affects the scalp, face and body. "With an estimated 90% of patients with seborrheic dermatitis believed to have affected areas on the scalp as well as on the face and body, this complete treatment system can help patients effectively manage this irritating and often embarrassing condition," says Al Altomari, CEO of Barrier Therapeutics. The pharmaceutical firm will handle assemblage, distribution, pricing, marketing, promotion and sale of the kits and will receive all proceeds from sales. Xolegel Duo will be available by prescription in June...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.